Kroner Paul T, Mareth Karl, Raimondo Massimo, Lee David D, Alsaad Ali, Aslam Nabeel, Abader Peter, Wadei Hani M
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
Department of Medicine, Mayo Clinic, Jacksonville, FL.
Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):160-168. doi: 10.1016/j.mayocpiqo.2019.03.006. eCollection 2019 Jun.
To study the prevalence, etiology, and outcome of acute pancreatitis (AP) in kidney transplant and stage 5 chronic kidney disease (CKD) populations in comparison to a non-CKD cohort.
Using the Nationwide Inpatient Sample database, we identified patients with acute pancreatitis as the primary discharge diagnosis, after which propensity scores were used to create 2 cohorts of patients: 1 with CKD (n=13,425) and 1 without CKD (n=13,425). The CKD group was subsequently subdivided into dialysis-independent stage 5 CKD (n=690), dialysis-dependent stage 5 CKD (n=11,415), and kidney transplant recipients (n=1320). Patients younger than 18 years old, those who received a kidney transplant during the incident admission, and pancreas transplant recipients were excluded.
The adjusted odds ratios (ORs) of AP were comparable between the no CKD, stage 5 CKD, and kidney transplant populations. Adjusted inpatient mortality was highest in patients with dialysis-dependent stage 5 CKD (OR, 2.72; 95% CI, 2.2-3.3; <.01), followed by kidney transplant recipients (OR, 2.29; 95% CI, 1.12-4.51; =.02), compared to the non-CKD group. Patients with stage 5 CKD experienced higher rates of shock and intensive care unit admission and had more prolonged and costly hospitalizations than the non-CKD group (<.01 for all). Hypercalcemia was the most common cause of AP in both dialysis-dependent and dialysis-independent patients with stage 5 CKD, while viral and drug-induced pancreatitis were more prevalent in the transplant recipients.
Despite comparable adjusted prevalence of AP among the stage 5 CKD, transplant, and non-CKD populations, mortality, morbidity, and resource utilization were higher in the patients with stage 5 CKD and transplant recipients. Hypercalcemia is the most common cause of AP in the stage 5 CKD population irrespective of dialysis requirement.
与非慢性肾脏病(CKD)队列相比,研究肾移植和5期慢性肾脏病(CKD)人群中急性胰腺炎(AP)的患病率、病因及转归。
利用全国住院患者样本数据库,我们将急性胰腺炎作为主要出院诊断的患者识别出来,之后使用倾向评分创建两组患者:一组为CKD患者(n = 13425),另一组为非CKD患者(n = 13425)。CKD组随后又细分为非透析依赖的5期CKD患者(n = 690)、透析依赖的5期CKD患者(n = 11415)和肾移植受者(n = 1320)。排除年龄小于18岁的患者、在本次入院期间接受肾移植的患者以及胰腺移植受者。
非CKD、5期CKD和肾移植人群中AP的校正比值比(OR)具有可比性。与非CKD组相比,透析依赖的5期CKD患者校正后的住院死亡率最高(OR,2.72;95%可信区间[CI],2.2 - 3.3;P <.01),其次是肾移植受者(OR,2.29;95% CI,1.12 - 4.51;P =.02)。5期CKD患者休克和入住重症监护病房的发生率更高,住院时间更长且费用更高,与非CKD组相比差异均有统计学意义(P均<.01)。高钙血症是透析依赖和非透析依赖的5期CKD患者中AP最常见的病因,而病毒和药物性胰腺炎在移植受者中更为常见。
尽管5期CKD、移植和非CKD人群中AP的校正患病率具有可比性,但5期CKD患者和移植受者的死亡率、发病率及资源利用率更高。无论是否需要透析,高钙血症都是5期CKD人群中AP最常见的病因。